Education
About Us
Working with TipRanks
Follow Us
Neuphoria Therapeutics (NEUP)
NASDAQ:NEUP
RESEARCH TOOLSreports
Total Valuation
Neuphoria Therapeutics has a market cap or net worth of $8.64M. The enterprise value is ―.
Market Cap$8.64M
Enterprise Value―
Share Statistics
Neuphoria Therapeutics has 1,757,027 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,757,027
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Neuphoria Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee0.00
Profits Per Employee-1.94M
Employee Count8
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Neuphoria Therapeutics is ―. Neuphoria Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Neuphoria Therapeutics had revenue of 0.00 and earned -15.49B in profits. Earnings per share was -1.02.
Revenue0.00
Gross Profit-434.45K
Operating Income-17.89B
Pretax Income-10.27M
Net Income-15.49B
EBITDA-9.84M
Earnings Per Share (EPS)-1.02
Cash Flow
In the last 12 months, operating cash flow was -4.90M and capital expenditures 0.00, giving a free cash flow of -4.43M billion.
Operating Cash Flow-4.90M
Free Cash Flow-4.43M
Free Cash Flow per Share-2.52
Dividends & Yields
Neuphoria Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.17
52-Week Price Change-61.60%
50-Day Moving Average5.14
200-Day Moving Average4.95
Relative Strength Index (RSI)59.67
Average Volume (3m)13.52K
Important Dates
Neuphoria Therapeutics upcoming earnings date is Feb 20, 2025, TBA Not Confirmed.
Last Earnings DateAug 21, 2024
Next Earnings DateFeb 20, 2025
Ex-Dividend Date―
Financial Position
Neuphoria Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Neuphoria Therapeutics has paid -87.32M in taxes.
Income Tax-87.32M
Effective Tax Rate―
Enterprise Valuation
Neuphoria Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Neuphoria Therapeutics has $8.08M in cash and marketable securities with AU$254.01K in debt, giving a net cash position of -$7.83M billion.
Cash & Marketable Securities$8.08M
Total DebtAU$254.01K
Net Cash-$7.83M
Net Cash Per Share-$4.46
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Neuphoria Therapeutics is $21.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$21.00
Price Target Upside288.89% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―